

Cathepsin B - Pipeline Review, H2 2020

<https://marketpublishers.com/r/CAE1493B686DEN.html>

Date: October 2020

Pages: 33

Price: US\$ 3,500.00 (Single User License)

ID: CAE1493B686DEN

Abstracts

Cathepsin B - Pipeline Review, H2 2020

SUMMARY

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Cathepsin B - Pipeline Review, H2 2020, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Infectious Disease, Gastrointestinal and Immunology which include indications Alzheimer's Disease, Autoimmune Disorders, Cancer Pain, Ebolavirus Infections (Ebola Hemorrhagic Fever), Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Schistosomiasis mansoni Infections and Traumatic Brain Injury. Furthermore, this report also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical

trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1)

The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Overview

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics
Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics
Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Companies
Involved in Therapeutics Development

ALSP Inc

Aviex Technologies LLC

Phelix Therapeutics LLC

Virobay Inc

Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Drug Profiles

ALP-496 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-0213W - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIBP-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cathepsin B for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Dormant Products
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Product Development Milestones
Featured News & Press Releases
Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent
Jan 25, 2016: ALSF invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by ALSP Inc, H2 2020

Pipeline by Aviex Technologies LLC, H2 2020

Pipeline by Phelix Therapeutics LLC, H2 2020

Pipeline by Virobay Inc, H2 2020

Dormant Projects, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Cathepsin B - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/CAE1493B686DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAE1493B686DEN.html>